SCHEMBL327743

SCHEMBL327743

CC1(C)NCCc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.43
HTR2C P28335 1/20 0.43
KDM1A O60341 1/20 0.41
PNMT P11086 1/20 0.39
CD44 P16070 1/20 0.39
MAOB P27338 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29674239 1.00 HTR2A (0.43) HTR2AHTR2CKDM1APNMTCD44
Hydrochloric Acid SCHEMBL1952104 0.98 HTR2A (0.42) HTR2AHTR2CKDM1APNMTCD44
SCHEMBL26327444 0.88 KDM1A (0.46) HTR2AKDM1A
SCHEMBL5575236 0.80 KDM1A (0.46) HTR2AHTR2CKDM1APNMTCD44
SCHEMBL29705936 0.80 HTR2A (0.41) HTR2AHTR2CKDM1APNMTCD44
SCHEMBL24124810 0.80 HTR2A (0.41) HTR2AHTR2CKDM1APNMTCD44
SCHEMBL3542185 0.78 ALDH1A1 (0.43) HTR2A
SCHEMBL9374419 0.77 CYP3A4 (0.42) HTR2AKDM1A
SCHEMBL8818780 0.77 HTR2A (0.39) HTR2AHTR2CKDM1APNMTCD44
SCHEMBL19223430 0.77 PRCP (0.39) HTR2AHTR2CKDM1APNMTCD44

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230350294-A1 Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-11-02 US disclosed
US-11768434-B2 Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-26 US disclosed
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 US disclosed
CN-114901652-A Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders 比亚尔R&D投资股份公司 2022-08-12 CN disclosed
EP-4031540-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Bial-R&D Investments, S.A. (PT) 2022-07-27 EP disclosed
US-20220154232-A1 Benzylisoquinoline Alkaloids (BIA) Producing Microbes, and Methods of Making and Using the Same HERCULES CAPITAL, INC., AS AGENT 2022-05-19 US disclosed
US-11214819-B2 Benzylisoquinoline alkaloids (BIA) producing microbes, and methods of making and using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-01-04 US disclosed
EP-3865580-A1 BENZYLISOQUINOLINE ALKALOIDS (BIA) PRODUCING MICROBES, AND METHODS OF MAKING AND USING THE SAME The Board of Trustees of the Leland Stanford Junior University (US) 2021-08-18 EP disclosed
US-20210189445-A1 Benzylisoquinoline Alkaloids (BIA) Producing Microbes, and Methods of Making and Using the Same HERCULES CAPITAL, INC., AS AGENT 2021-06-24 US disclosed
US-10988787-B2 Benzylisoquinoline alkaloids (BIA) producing microbes, and methods of making and using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-04-27 US disclosed
CN-1255917-A Anti-convulsant isoquinolyl-benzamide derivatives SMITHKLINE BEECHAM PLC (GB) 2000-06-07 CN disclosed
CN-1046713-C Tetrahydroisoquinoline compounds, pharmaceutical compositions containing them, and their preparation and use KNORR CO LTD (GB) 1999-11-24 CN disclosed
CN-1212020-A Method and compositions for analyzing nucleic acid molecules utilizing sizing techniques RAPIGENE INC (US) 1999-03-24 CN disclosed
CN-1212021-A Method and compositions for determining sequence of nucleic acid molecules RAPIGENE INC (US) 1999-03-24 CN disclosed
CN-1212019-A Methods and compositions for detecting ligand pair binding using non-fluorescent labels RAPIGENE INC (US) 1999-03-24 CN disclosed
US-5686458-A Quinazoline deriviates for treating peptic ulcer YUHAN CORPORATION (KR) 1997-11-11 US disclosed
WO-1997036588-A2 USE OF 1,1-DIALKYL-1,2,3,4-TETRAHYDROISOQUINOLINES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF PSYCHOSIS AND PAIN LEDERLE (JAPAN), LTD. (JP) 1997-10-09 WO disclosed
CN-1128992-A Therapeutic agents KNORR CO LTD (DE) 1996-08-14 CN disclosed
EP-0677049-A1 QUINAZOLINE DERIVATIVES YUHAN CORPORATION, LTD. (KR) 1995-10-18 EP disclosed
WO-1994014795-A1 QUINAZOLINE DERIVATIVES YUHAN CORPORATION (KR) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, CLN6 HTR2A 828/4885HTR2C 853/4885KDM1A 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.